The Microbiome in Patients With Inflammatory Diseases

Area of Science:

• Microbiology
• Gastroenterology
• Immunology

Background:

• Microbial dysbiosis, an imbalance in gut bacteria, is increasingly recognized in inflammatory bowel disease (IBD) pathogenesis.
• Historically, IBD microbiome research focused on composition; functional analysis is now expanding due to technological advancements.
• Preclinical data strongly suggest a causal role for gut microbiome changes in IBD development.

Purpose of the Study:

• To review current human IBD microbiome findings.
• To elucidate cause-effect relationships between the gut microbiome and IBD.
• To discuss microbiome-based strategies for IBD diagnosis, therapy, and management.

Main Methods:

• Review of existing human IBD microbiome studies.
• Analysis of preclinical and clinical evidence.
• Synthesis of data on microbiome function and metabolites in IBD.

Main Results:

• Accumulating correlative evidence indicates microbial dysbiosis parallels IBD incidence.
• Functional aspects of microbial dysbiosis are crucial in IBD pathogenesis.
• Gut microbiome metabolites play a significant role in IBD development.

Conclusions:

• Modulating gut microbiome state and function holds therapeutic potential for IBD.
• Microbiome-based interventions may offer novel approaches for IBD treatment and management.
• Further research is needed to fully establish the causal role of the gut microbiome in IBD and optimize microbiome-based therapies.